Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
1(33%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
1
33%

Phase Distribution

0

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution1 total trials
N/ANon-phased studies
1(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Completed(2)

Detailed Status

Completed2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
N/A

Trials by Phase

N/A1 (100.0%)

Trials by Status

completed267%
recruiting133%

Recent Activity

1 active trials
Showing 3 of 3
completed

Evaluation of Diagnostic Efficiency of PIVKA-II and Other Tumor Markers in HCC

NCT03047603
completed

PIVKA-II Combined With Alpha-Fetoprotein for Diagnostic and Prognostic Value of Hepatic Tumors in Infants

NCT03645655
recruitingnot_applicable

Combining Biomarkers (AFP, AFP-L3, and PIVKA-II) and Image Tools for Early Detection of Hepatocellular Carcinoma

NCT04414956

Clinical Trials (3)

Showing 3 of 3 trials
NCT03047603

Evaluation of Diagnostic Efficiency of PIVKA-II and Other Tumor Markers in HCC

Completed
NCT03645655

PIVKA-II Combined With Alpha-Fetoprotein for Diagnostic and Prognostic Value of Hepatic Tumors in Infants

Completed
NCT04414956Not Applicable

Combining Biomarkers (AFP, AFP-L3, and PIVKA-II) and Image Tools for Early Detection of Hepatocellular Carcinoma

Recruiting

All 3 trials loaded

Drug Details

Intervention Type
DIAGNOSTIC TEST
Total Trials
3